ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE
Hormone-receptor positive breast cancer is the most common molecular subtype and represents 60–75 % of all breast cancers (BC). The presence of specific molecular targets such as the estrogen/progesterone receptor determines the use of hormone therapy for patients with this subtype. Tamoxifen, a sel...
Saved in:
| Main Authors: | D. B. Erdyneeva, N. N. Babyshkina, T. A. Dronova, S. V. Vtorushin, E. M. Slonimskaya, V. N. Stegniy, N. V. Cherdyntseva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2020-09-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1540 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ROLE OF MORPHOLOGICAL AND GENETIC STRUCTURAL CHARACTERISTICS OF ESTROGEN RECEPTOR ALPHA IN THE DEVELOPMENT OF RESISTANCE TO ENDOCRINOTHERAPY WITH TAMOXIFEN IN PATIENTS WITH LUMINAL BREAST CANCER
by: Е. М. Slonimskaya, et al.
Published: (2016-02-01) -
Integration of phosphoinositide 3-kinase (PI3K) and transforming growth factor β1 (TGF-β1) signaling cascades: role in the therapeutic inefficiency of tamoxifen
by: N. N. Babyshkina, et al.
Published: (2023-12-01) -
Features of ovarian steroidogenesis and endometrial hypertrophy during adjuvant therapy with tamoxifen in premenopausal patients with hormone-dependent breast cancer
by: A. Yu. Goryainova, et al.
Published: (2023-05-01) -
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
by: Jaime D. Lewis, et al.
Published: (2014-11-01) -
CYP2D6-GENOTYPING IN THE ASSESSMENT OF THE EFFECTIVENESS OF THERAPY WITH TAMOXIFEN IN PATIENTS WITH ADVANCED HORMONE RECEPTOR-POSITIVE BREAST CANCER
by: L. N. Lyubchenko, et al.
Published: (2017-12-01)